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Background: Preterm birth is the most common cause of neonatal morbidity and mortality. Postponing delivery
for 48 hours with tocolytics to allow for maternal steroid administration and antenatal transportation to a centre
with neonatal intensive care unit facilities is the standard treatment for women with threatening preterm delivery in
most centres. However, there is controversy as to which tocolytic agent is the drug of first choice. Previous trials
have focused on tocolytic efficacy and side effects, and are probably underpowered to detect clinically meaningfull
differences in neonatal outcome. Thus, the current evidence is inconclusive to support a balanced recommendation
for clinical practice. This multicenter randomised clinical trial aims to compare nifedipine and atosiban in terms of
neonatal outcome, duration of pregnancy and maternal side effects.
Methods/Design: The Apostel III trial is a nationwide multicenter randomised controlled study. Women with
threatened preterm labour (gestational age 25 – 34 weeks) defined as at least 3 contractions per 30 minutes, and
1) a cervical length of ≤ 10 mm or 2) a cervical length of 11-30 mm and a positive Fibronectin test or 3) ruptured
membranes will be randomly allocated to treatment with nifedipine or atosiban. Primary outcome is a composite
measure of severe neonatal morbidity and mortality. Secondary outcomes will be time to delivery, gestational age
at delivery, days on ventilation support, neonatal intensive care (NICU) admittance, length admission in neonatal
intensive care, total days in hospital until 3 months corrected age, convulsions, apnoea, asphyxia, proven meningitis,
pneumothorax, maternal side effects and costs. Furthermore, an economic evaluation of the treatment will be
performed. Analysis will be by intention to treat principle. The power calculation is based on an expected 10%
difference in the prevalence of adverse neonatal outcome. This implies that 500 women have to be randomised
(two sided test, β 0.2 at alpha 0.05).
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Discussion: This trial will provide evidence on the optimal drug of choice in acute tocolysis in threatening
preterm labour.
Trial registration: Clinical trial registration: NTR2947, date of registration: June 20th 2011.
Keywords: Preterm birth, Tocolytics, Nifedipine, Atosiban, Outcome, Drug safetyBackground
Preterm birth is the most common cause of neonatal
morbidity and mortality worldwide [1]. In the USA, the
rate of infants born before 37 weeks gestation is 12-13%;
while in Europe and other developed countries these
rates vary between 5-11% [2,3]. Preterm birth accounts
for approximately 75% of all neonatal deaths and 50% of
childhood neurological morbidities [4,5] and puts a fi-
nancial burden on the public health care system [6].
Neurodevelopmental impairments are frequently pre-
sent in preterm infants, and are associated with gestatio-
nal age [7]. Neonatal outcome is enhanced by antenatal
corticosteroid administration and in-utero transfer to a
tertiary care centre [8,9]. To optimize outcome in threat-
ening preterm delivery, postponing delivery for 48 hours
with tocolytic agents is common practice in most peri-
natal centres [10], to allow maximal effect of maternal
steroid administration and transportation of the mother
to a centre with neonatal intensive care unit (NICU)
facilities.
Several types of tocolytic drugs are commonly used as
treatment in preterm labour. These include the β adre-
noceptor agonist ritodrine hydrochloride, the oxytocin
receptor antagonist atosiban and the calcium channel
blocking agent nifedipine. Several meta-analyses indicate
that tocolytic drugs are superior to placebo or other
tocolytics at delaying delivery by 48 hours and 7 days
[11,12].
However, controversy exists as to which tocolytic is
the drug of first choice. The ideal drug of choice should
be efficient in postponing preterm labour, have a favor-
able safety profile in both mother and fetus, and should
reduce neonatal morbidity and mortality at a reasonable
cost.
Studies on β adrenoceptor agonists have shown mixed
results for postponing delivery compared to placebo
[13]. As β adrenoceptor agonists have substantial side
effects, use has been largely abandoned from clinical
practice. A Cochrane review on calcium channel bloc-
kers for inhibiting preterm labour showed that nifedi-
pine significantly reduced delivery within seven days of
receiving treatment as compared with any other tocoly-
tic agent (relative risk (RR) 0.76; 95% confidence interval
(CI) 0.60 to 0.97) [14]. In addition, as compared to other
tocolytics, calcium channel blockers also reduced thefrequency of neonatal respiratory distress syndrome (RR
0.63; 95% CI 0.46 to 0.88), necrotising enterocolitis (RR
0.21; 95% CI 0.05 to 0.96), intraventricular haemorrhage
(RR 0.59 95% CI 0.36 to 0.98) and neonatal jaundice (RR
0.73; 95% CI 0.57 to 0.93), and the requirement for
women to have treatment ceased for adverse drug re-
action (RR 0.14; 95% CI 0.05 to 0.36). The Cochrane re-
view on oxytocin receptor antagonists for inhibiting
preterm labour failed to demonstrate the superiority of
atosiban over β adrenoceptor agonists (RR 0.98; 95% CI
0.68 to 1.41) or placebo (RR 2.5; 95% CI 0.51 to 12.35)
in terms of tocolytic efficacy or infant outcomes [15].
On the other hand, atosiban is thought to be completely
safe for the mother, whereas nifedipine may cause severe
hypotension and fetal death [16]. Such side effects could
however not be demonstrated in a previous nationwide
study in The Netherlands [17]. Two small studies did
not show a difference in effectiveness between nifedipine
and atosiban [18,19], however, more side effects were
observed with the use of nifedipine, consisting of hy-
potension, tachycardia headache and vertigo. Neonatal
outcome was not reported in one study, the other study
did not show a difference.
Recently, a larger study was published, (n = 145) and
found fewer failures within 48 hours for atosiban com-
pared with nifedipine [20]. However, nifedipine was asso-
ciated with a longer postponement of delivery. Neonatal
morbidity was comparable between the two groups, al-
though the number of neonatal admissions to the NICU
and length of postnatal hospital admission was signifi-
cantly higher in the atosiban group as compared with the
nifedipine group. The main outcome measure of these
3 trials were tocolytic efficacy and tolerability, but the
trails may be underpowered to detect clinically meaning-
full effects in neonatal outcome. Therefore, the evidence
remains inconclusive to support a balanced recommen-
dation for clinical practice as the ultimate goal of to-
colysis is not only to postpone delivery, but to improve
neonatal outcome. This multicenter randomised clinical
trial aims to compare nifedipine and atosiban in terms
of neonatal outcome, duration of pregnancy, maternal
side effects and costs. The study is conducted within
the Dutch Obstetric Consortium, a collaborative effort
of obstetric clinics in The Netherlands to perform clinical
trials.
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Aims
The objective of this study is to compare the effective-
ness of the tocolytic agents nifedipine and atosiban in
the improvement of neonatal outcome in women with
threatened preterm labour with a gestational age bet-
ween 25 – 34 weeks. Outcome is measured in terms of
neonatal mortality and morbidity (chronic lung disease,
severe intraventricular haemorrhage, periventricular leu-
comalacia, culture proven sepsis, necrotizing enterocoli-
tis), gestational age at delivery, maternal side effects and
costs.
Participants/eligibility criteria
We included women with a high risk of preterm birth.
Women, aged ≥18 years, with threatened preterm labour
and a gestational age between 25 and 34 weeks are eli-
gible for participation in the Apostel III trial. The diag-
nosis of threatened preterm labour is defined by uterine
contractions, at least 3 contractions per 30 minutes, and
one of the following: 1) a cervical length of ≤10 mm or
2) a cervical length of 11-30 mm and a positive Fibro-
nectin test or 3) ruptured amniotic membranes. Patients
with singleton or twin pregnancies are eligible, inde-
pendent of the position of the fetus.
Exclusion criteria are presence of a contra-indication
for tocolysis (severe vaginal bleeding, signs of fetal dis-
tress or intrauterine infection, hypertension or use of
anti-hypertensive medication, myocardial infarction (<1
month), unstable angina pectoris), cerclage, > 5 cm cer-
vical dilatation, neonates suspected of chromosomal or
structural anomalies and tocolytic treatment for >6 hours
prior to arrival in a participating centre.
Procedures, recruitment, randomization and collection of
baseline data
The study will be a nationwide multicentre rando-
mised controlled trial conducted within the Dutch Obs-
tetric Consortium. The Dutch Obstetric Consortium
is a research collaboration of obstetric clinics in the
Netherlands. All 10 Dutch perinatal centres with NICU fa-
cilities will participate in the trial. In addition, 10 large
teaching hospitals in the Netherlands and 2 perinatal cen-
tres in Belgium will participate in this trial.
Eligible women will be identified by the staff and/or
local research coordinator of the participating hospitals.
After counselling and reading the patient information
form, patients will be asked for written informed con-
sent. We will provide patient information in Dutch and
English. After informed consent, baseline demographics,
obstetric and medical history of patient will be en-
tered in a web-based database, which will also facili-
tate randomisation. Randomisation will be performed
by a web based computerized program using permuted-block randomisation. Randomisation allocation will be in
a 1:1 ratio for Nifedipine or Atosiban, block size will be 4.
As this is a comparison of oral medication and intra-
venous medication, and as both group are treated with
active medication, the study will not be blinded.
Interventions
Patients are allocated to nifedipine or atosiban for
48 hours. In the nifedipine group, the initial dose will be
2 × 10 mg nifedipine capsules orally in the first hour,
followed by 20 mg nifedipine retard per 6 hours for the
next 47 hours. In the first hour after starting nifedipine,
blood pressure and heart rate will be measured every
15 minutes. If blood pressure remains within the normal
limits, treatment will be continued and blood pressure
and heart rate will be measured 4 times every 24 hours.
In the atosiban group, a bolus injection of 6.75 mg
i.v. in 1 minute, followed by 18 mg/hour for 3 hours,
followed by a maintenance dosage of 6 mg/hour for
45 hours.
Antenatal corticosteroids will be administered accord-
ing to the clinical guideline. Prophylactic treatment with
antibiotics is at the decision of the attending physician.
When the attending physician considers escape medica-
tion, this can be discussed with a perinatologist who will
be available for study questions 24 hours per day.
Outcome measures
Primary outcome measures
The primary outcome measure will be a composite of
adverse neonatal outcome, including bronchopulmon-
ary dysplasia (BPD), periventricular leucomalacia (PVL) >
grade 1, intraventricular haemorrhage > grade 2, necrotis-
ing enterocolitis (NEC) > stage 1 [21], culture proven sep-
sis and in-hospital death.
The diagnosis of BPD will be made according to the
international consensus guideline as described by Jobe
and Bancalari [22] at time of discharge home or at 36
weeks of corrected gestational age. PVL > grade 1 and
intraventricular haemorrhage > grade 2 will be diagnosed
by repeated neonatal cranial ultrasound by the neonat-
ologist according to the guidelines on neuro imaging de-
scribed by de Vries [23] and Ment et al. [24] NEC will
be diagnosed according to Bell [21], > stage 1. Culture
proven sepsis is diagnosed on the combination of clinical
signs and positive blood cultures.
Secondary outcome measures
Secondary outcomes will be time to delivery, gestational
age at delivery, days on ventilation support, length of ad-
mission in neonatal intensive care, convulsions, apnoea,
asphyxia, proven meningitis, pneumothorax, total days
in hospital until 3 months corrected age. Furthermore
we will examine differences in maternal mortality and
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medication.
Follow-up of women and infants
All details of delivery, maternal and neonatal assess-
ments during pregnancy and postpartum are recorded in
a web-based Case Report Form (CRF). Details of neo-
natal admission are also recorded. Long-term follow up
of children is dependent on future funding.
Statistical issues
Sample size
The sample size is calculated based on a 10%- reduction
of the composite poor neonatal outcome from 25% in
the atosiban arm to 15% in the nifedipine arm. With a
beta of 0.2 and alpha of 0.05 we have to randomize 500
patients (250 in each arm).
Data analysis
Data will be analyzed according to the intention to treat
principle. The main outcome variable, ‘adverse neonatal
outcome’, will be assessed by calculating rates in the two
groups, relative risks and 95% confidence intervals as
well as numbers needed to treat. To evaluate the poten-
tial of each of the strategies, we will also perform a per
protocol analysis, taking into account only those women
that were treated according to protocol. Time to delivery
will be evaluated by Cox proportional hazards regression
and Kaplan-Meier estimates, with account for differing
durations of gestation at entry, and will be tested with
the Log rank test. The other secondary outcome mea-
sures will be approached similarly to the primary out-
come measure.
Furthermore, we plan to separately report on the treat-
ment effect in the following subgroups: 1) PPROM
versus intact membranes 2) GA < 30 weeks versus > 30
weeks, 3) fibronectin positive women only, 4) women with
a cervix length < 10 mm, 5) multiple pregnancies, and 6)
women with a history of preterm birth.
Interim analysis
An interim analysis is planned after the follow up data
of the first 150 women that have been included is ob-
tained. The interim analysis will be performed by an in-
dependent person and results will be reported to a data
safety and monitoring committee (DSMC) for safety and
relevance. As an indication, the trial will be stopped if
there is a significant difference in the primary outcome,
i.e. a poor neonatal outcome, at p < .005 (2-sided). How-
ever, the DSMC is free to make its own judgment.
Data safety monitoring committee
Serious Adverse Events (SAEs) and Suspected Unexpec-
ted Serious Adverse Reactions (SUSARs) will be reportedto a Data Safety Monitoring Committee (DSMC). The
DSMC can decide to perform an extra interim analysis
and, if indicated, terminate the trial prematurely.
Economic evaluation
We plan an economic evaluation of the costs and health
effects of nifedipine and atosiban. The economic evalu-
ation will be set up as a cost-effectiveness analysis (CEA)
in which we will calculate the cost per prevented case of
poor neonatal outcome. To evaluate cost-effectiveness
within a long term horizon, downstream costs associated
with poor neonatal outcome are estimated, and included
in the analysis as a cost-to-benefit ratio. In a cost-utility
analysis, with QALYs calculated from average life ex-
pectancy and utilities for severe neonatal morbidity,
the incremental cost-effectiveness will be expressed
as costs per QALY gained. In sensitivity analyses, the
impact of parameter uncertainty and stochastic un-
certainty is assessed, and the results are visualized in
cost-effectiveness planes and cost-effectiveness accep-
tability curves.
In our economic analysis, we distinguish three cost
stages (antenatal stage, delivery/childbirth stage and post-
natal stage), and three cost categories: 1) direct medical
costs i.e. all costs in the health care sector 2) direct non-
medical costs i.e. costs outside the health care sector that
are affected by health status or health care, and 3) indirect
costs of the pregnant woman and her partner, for example
costs of sick leave. For each stage and cost category, costs
are measured as the volumes of resources used multiplied
with appropriate valuations based on national reference
prices, cost-per-unit estimates, or reimbursement fees.
Volumes of health care resource use are measured
alongside the clinical study as part of the CRF as well as
with questionnaires. Questionnaires will be based on the
iMTA Medical Consumption Questionnaire (MCQ) and
the Productivity Costs Questionnaire (PCQ) to collect
data regarding health care consumption (e.g. number of
GP contacts or outpatient visits, hospital admissions,
and drug use), travel and time costs and productivity
loss during follow-up at 6-month intervals. These ques-
tionnaires will be adapted to include only resources rele-
vant to this study, and to document absence from paid
work by the partners.
For an evaluation from a societal perspective, valua-
tions of direct medical resources are estimated compris-
ing ‘true economic’ costs, i.e. including shares of fixed
costs and hospital overheads. Dutch reference prices are
used where available. Otherwise, costs per unit are esti-
mated for at least one teaching and one non-teaching
hospital. Calculations based on reimbursement fees is ad-
ded to our analysis to represent the payers perspective.
Indirect costs are quantified but remain unvalued.
Study-specific costs are excluded from analysis.
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Discussion
Preterm birth is an important cause of neonatal morbid-
ity and mortality. Outcome of preterm infants can be
improved and health care consumption and costs re-
duced by postponing delivery for 48 hours with tocolytic
agents to allow maximal effect of maternal steroid admin-
istration and transportation of the mother to a centre with
NICU facilities. The optimal type of tocolytic drug should
improve neonatal outcome, be effective in delaying deliv-
ery, and safe for both mother and fetus. This trial will pro-
vide evidence on these subjects on the tocolytic drugs
nifedipine and atosiban.
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